Stocks and Investing Stocks and Investing
Wed, November 27, 2019
Tue, November 26, 2019

Charles Duncan Reiterated (ACAD) at Buy with Increased Target to $70 on, Nov 26th, 2019


Published on 2024-10-26 18:37:54 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $63 to $70 on, Nov 26th, 2019.

Charles has made no other calls on ACAD in the last 4 months.



There are 6 other peers that have a rating on ACAD. Out of the 6 peers that are also analyzing ACAD, 2 agree with Charles's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Initiated at Hold and Held Target at $44 on, Thursday, October 24th, 2019
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $28 on, Tuesday, September 3rd, 2019


These are the ratings of the 4 analyists that currently disagree with Charles


  • Gregory Renza of "RBC Capital" Initiated at Buy and Held Target at $60 on, Tuesday, October 1st, 2019
  • Marc Goodman of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $50 on, Friday, September 13th, 2019
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Tuesday, September 10th, 2019
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $60 on, Monday, September 9th, 2019
Contributing Sources